↓ Skip to main content

Dove Medical Press

Article Metrics

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia

Overview of attention for article published in Neuropsychiatric Disease and Treatment, August 2012
Altmetric Badge

Mentioned by

twitter
1 tweeter
video
1 video uploader

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
26 Mendeley
Title
Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
Published in
Neuropsychiatric Disease and Treatment, August 2012
DOI 10.2147/ndt.s32581
Pubmed ID
Authors

Cynthia Samtani, Sliwa, Fu, Turkoz, Larry Alphs

Abstract

A post hoc analysis from a multiphase trial with open-label transition and maintenance phases, a double-blind relapse prevention phase, and an optional open-label extension examined the long-term tolerability with continuous once-monthly injectable paliperidone palmitate 39, 78, 117, or 156 mg (25, 50, 75, or 100 mg equivalents [mg eq] of paliperidone) in subjects with recently diagnosed (≤5 years; n = 216) versus chronic illness (>5 years; n = 429) schizophrenia.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 26 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 19%
Student > Bachelor 1 4%
Other 1 4%
Professor > Associate Professor 1 4%
Unknown 18 69%
Readers by discipline Count As %
Medicine and Dentistry 6 23%
Neuroscience 1 4%
Unspecified 1 4%
Unknown 18 69%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 August 2012.
All research outputs
#9,475,826
of 12,372,641 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,527
of 2,084 outputs
Outputs of similar age
#85,491
of 126,439 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#19
of 28 outputs
Altmetric has tracked 12,372,641 research outputs across all sources so far. This one is in the 20th percentile – i.e., 20% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,084 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 126,439 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.